Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·1998
A new kit for preparing rhenium-186-labeled hydroxyethylidene diphosphonate (186Re-HEDP) shows potential as a bone-seeking agent for diagnosis and therapy. In vivo studies confirm its bone-targeting ability and suitability for imaging bone lesions.
Area of Science:
Nuclear medicine
Radiopharmaceutical chemistry
Background:
Developing effective bone-seeking radiopharmaceuticals is crucial for skeletal imaging and therapy.
Hydroxyethylidene diphosphonate (HEDP) is a known bone-targeting agent.
Purpose of the Study:
To develop and evaluate a lyophilized kit for preparing rhenium-186-labeled HEDP (186Re-HEDP) as a dual-purpose diagnostic and therapeutic bone agent.
Main Methods:
A lyophilized kit of HEDP was prepared for labeling with 186Re.
High-pressure liquid chromatography (HPLC) was used for analysis and purification.
In vivo studies were conducted in animal models to assess bone uptake and clearance.
Main Results:
186Re-HEDP was successfully prepared, yielding a mixture of components.
Both the mixture and the HPLC-purified main component demonstrated bone-seeking properties with slow blood and soft-tissue clearance.
HPLC purification led to a slight improvement in imaging quality.
In animal models with induced osteogenetic activity, the traumatized leg showed 1.7-1.9 times higher bone uptake than the normal leg, with lesion-to-normal bone ratios of 4-5.4.
Conclusions:
The developed lyophilized kit provides a viable method for preparing 186Re-HEDP.
186Re-HEDP exhibits favorable characteristics for bone imaging and therapy, including good bone targeting and retention.
The agent effectively highlights areas of increased osteogenetic activity, suggesting its potential for diagnosing and treating bone conditions.
